Stevenage, UK, and Boca Raton, Florida, US, April 11, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system has partnered with the Cell and Gene Therapy Catapult (CGT Catapult) to establish large-scale, commercial-ready manufacturing for its cell therapy platforms. CGT Catapult is an independent technology and innovation organisation specialising in the advancement of the cell and gene therapy industry. It was established by and works in partnership with Innovate UK.
INmune Bio’s therapies harness the innate immune system, the body’s first line of defense, to treat diseases including Alzheimer’s, prostate cancer, and recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic skin disorder. With active trials across the UK, Europe, Australia, Canada and the US, the company is advancing a diversified portfolio addressing significant unmet medical needs.
The collaboration builds on INmune Bio’s existing manufacturing base at the Royal Free Hospital and leverages CGT Catapult’s expertise at its Stevenage Manufacturing Innovation Centre. The initial focus is on scaling production of CORDStromTM, a promising therapy for RDEB. In a recent Phase 2 randomised trial, CORDStromTM reduced pain and itch while showing potential to improve skin integrity and disease activity. INmune Bio estimates that approximately 4,000 children with intermediate to severe RDEB in the US, UK and EU could benefit, positioning CORDStromTM for clinical trial supply and eventual Biologics License Application (BLA) and Marketing Authorisation Application (MAA) submissions. The Company believes that CORDStrom™ could be the first cell therapy to address the systemic nature of RDEB.
Following CORDStromTM, INmune Bio plans to transition production of INKmune®, its NK-priming cell medicine for solid tumours, to the same facility, supporting ongoing and future trials in the US and UK, including the Phase 2 study in metastatic castration-resistant prostate cancer.
This partnership with CGT Catapult accelerates the Company’s path to commercialisation by delivering efficient, scalable manufacturing while preserving operational control.
“INmune Bio’s therapies address important healthcare challenges, and we are delighted to be working with them to support their journey to becoming a commercial scale developer and manufacturer of cell therapies, and help them meet rising demand for their products. The decision to strengthen their presence in the UK will help ensure that patients here benefit from novel cell therapies and support the UK’s position as a global hub for advanced therapies.”
Matthew Durdy, Chief Executive of the CGT Catapult
“The collaboration with the team at CGT Catapult since starting to plan this transition has been a great experience of the sort of partnership needed to get these complex medicines from clinical trial to commercial delivery. The unmatched scale of this UK-based facility provides INmune Bio, with an exceptional platform to advance our next phase of corporate growth, developing and trialing UK-invented products. This partnership stands as an excellent example of cross-border collaboration, harnessing global expertise to potentially deliver groundbreaking treatments to market.”
Professor Mark Lowdell, CSO and co-founder of INmune Bio